WB NEET 2025 admissions: Revised schedule, provisional list of candidates eligible for choice filling released- details

West Bengal- The West Bengal Medical Counselling Committee (WBMCC) has revised the WB National Eligibility and Entrance Test-Undergraduate (NEET UG) round 1 Reporting and Admission schedule for the academic year 2025 for State Quota, Private Management Quota and NRI Quota seats in West Bengal.

In this regard, WBMCC has released the tentative revised schedule as well as the revised provisional list of candidates eligible for Round 1 choice filling for Counselling of WB NEET UG 2025 for State Quota, Private Management Quota and NRI Quota seats in West Bengal.

As per the schedule, the WB NEET UG round 1 result has been published today, i.e. 23 August 2025, after 11 am. Following this, from today itself, from 12 noon to 5 pm, 25 & 26 August 2025, from 10 am to 4 pm, the Reporting and Admission of allotted candidates to the allotted Institute with the requisite original document, college requisite fee and bond will start.

Also Read: WB NEET Counselling 2025 temporarily suspended! Over 11,000 aspirants affected

Medical Dialogues had earlier reported that the WBMCC temporarily suspended the NEET UG counselling for the academic year 2025 for MBBS and BDS courses “till further orders”. The decision came just two days before the scheduled release of the round 1 seat allotment results, leaving reportedly over 11,000 medical aspirants in West Bengal in uncertainty.

The suspension was announced through an urgent notice a day before the announcement of seat allotment. The notice said, “West Bengal NEET UG Medical Dental 2025 counselling/admission has been kept in abeyance till further orders.”

This development came after the release of the revised provisional state merit list for 85% state quota seats on August 16.

The suspension had direct impact on a total of 11,178 candidates included in the provisional merit list. Thus, candidates seeking medical admission in West Bengal are still in limbo and are waiting for clarity from the authorities on when the admission process will resume.

To view the schedule, click the link below

https://medicaldialogues.in/pdf_upload/wbmcc-revises-wb-neet-2025-round-1-reporting-admission-schedule-result-released-today-298571.pdf

Powered by WPeMatico

Four new drugs for rare diseases on anvil, 5 medications for 7 ailments in mkt: VK Paul

New Delhi: India is making significant strides in the fight against rare diseases, with four new drugs currently in the pipeline and five already available in the market for the treatment of seven rare conditions, according to Niti Aayog member (health) Dr. VK Paul.

Speaking at an event here, Dr. Paul said that the launch of generic medications by the local companies has brought substantial relief to patients suffering from rare disorders.

Currently, 63 rare diseases are included under National Policy for Rare Diseases on recommendation of Central Technical Committee for Rare Diseases (CTCRD).
“For seven diseases, we have made significant progress. These seven diseases include Thalassemia, Wilson’s disease and Cystic Fibrosis… there are five drugs which are now available in the market,” Paul stated.
Four other drugs are on the anvil, he added.
According to PTI, he noted that NITI Aayog had shortlisted 13 disorders as a priority in 2023.
Paul stated that rare diseases are estimated to collectively affect close to nine crore Indians, making them both a health and societal challenge. He emphasised that with only a fraction of the 7,000 rare diseases having approved therapies, indigenous manufacturing, stronger registries, and multi-ministerial coordination must be prioritised.
He underlined that collective resolve must ensure faster diagnosis, equitable treatment, and an improved quality of life.
Paul also highlighted the importance of collaboration across academia, industry, and government so that quality and affordable treatments can be developed and research can be translated into lasting cures.
Department of Pharmaceuticals Secretary Amit Agrawal said the government under the PLI scheme for pharmaceuticals has been able to support production of drugs to treat eight rare diseases.
He noted that the government aims to treat rare diseases and orphan drugs as a strategic priority area among the priority areas with higher policy support.
Novartis MD & Country President Amitabh Dube said rare diseases affect over 300 million globally, with 70-90 million in India.
Acknowledging the progress made, he stressed the need for continued efforts to address the challenges faced by patients in the rare disease management.
“We have to create an ecosystem that encourages and enables R&D, reduces regulatory delays and values innovation so treatments can reach Indian patients faster,” he added.
He also advocated sustainable financing solutions to ensure access to emerging, advanced therapies that exceed Rs 50 lakh.

Powered by WPeMatico

Why bad arguments sound convincing: Ten tricks of logic that underpin vaccine myths

The biggest lie those who create and spread misinformation perpetrate is that they want you to think for yourself. They warn their target audience not to be “sheep” and not to let themselves be told what to believe by “mainstream” voices, the “deep state” or other bogey men.

Powered by WPeMatico

Why bad arguments sound convincing: Ten tricks of logic that underpin vaccine myths

The biggest lie those who create and spread misinformation perpetrate is that they want you to think for yourself. They warn their target audience not to be “sheep” and not to let themselves be told what to believe by “mainstream” voices, the “deep state” or other bogey men.

Powered by WPeMatico

Zone zero: The rise of effortless exercise

It can look almost too easy: athletes gliding along on a bike, runners shuffling at a pace slower than most people’s warm-up, or someone strolling so gently it barely seems like exercise at all. Yet this kind of effortless movement is at the heart of what’s becoming known as zone zero exercise.

Powered by WPeMatico

Zone zero: The rise of effortless exercise

It can look almost too easy: athletes gliding along on a bike, runners shuffling at a pace slower than most people’s warm-up, or someone strolling so gently it barely seems like exercise at all. Yet this kind of effortless movement is at the heart of what’s becoming known as zone zero exercise.

Powered by WPeMatico

Diagnosing diabetes may soon be as easy as breathing into a bag

In the U.S., one in five of the 37 million adults who has diabetes doesn’t know it. Current methods of diagnosing diabetes and prediabetes usually require a visit to a doctor’s office or lab work, both of which can be expensive and time-consuming. Now, diagnosing diabetes and prediabetes may be as simple as breathing.

Powered by WPeMatico

Rethinking phototherapy: Why skin color matters for infant jaundice

Jaundice is one of the most common medical issues in newborns, affecting nearly 80% of full-term infants in their first days of life. The condition occurs when excess bilirubin, a yellow pigment formed as red blood cells break down, builds up in the body. While mildcases usually resolve on their own, dangerously high bilirubin levels can cause brain damage or even death. The standard treatment, phototherapy, uses blue light to break bilirubin down into forms the body can excrete.

Powered by WPeMatico

Lymphoma itself, not just treatment, can trigger rapid immune system and tissue aging

A new study led by a team of researchers at Moffitt Cancer Center reveals that lymphoma can accelerate the biological aging of the immune system and other tissues, providing new insight into how cancer reshapes the body beyond tumor growth.

Powered by WPeMatico

New cancer drug boosts effectiveness of chemotherapy-even in resistant tumours: Study

A groundbreaking cancer drug could enhance how patients respond to chemotherapy even in treatment-resistant tumours.

The drug works by disarming a key defence mechanism that tumours use to protect themselves from treatment. In preclinical models, it has already shown promise in making chemotherapy-resistant cancers more responsive to therapy.

Chemotherapy is one of the most widely used cancer treatments, but it doesn’t always work as effectively as hoped. One major reason is that a specific group of the body’s own immune cells act as a barrier around tumours. These white blood cells known as macrophages surround the blood vessels inside tumours and act like gatekeepers, blocking helpful immune cells from entering and doing their job in supporting the responses to chemotherapy.

The King’s College London scientists, who have launched a spinout company Aethox Therapeutics, found that these macrophages make a protein called heme oxygenase-1 (HO-1), which helps shield the tumour from the immune system and block the effects of chemotherapy. The new drug, KCL-HO-1i, targets this protein.

Professor James Arnold, Head of Tumour Immunology Group, King’s College London, said: “We discovered that these macrophages in cancer play a key role in blocking chemotherapy. By targeting the enzyme they produce using KCL-HO-1i, we were able to help beneficial immune cells and chemotherapy drugs become significantly more effective. In laboratory models, even chemotherapy-resistant tumours became responsive to treatment, which is a really exciting step forward.”

Unlike many cancer treatments that require hospital visits, KCL-HO1i is designed to be taken at home as a tablet between chemotherapy sessions. This makes it easier for patients to incorporate into their treatment plans without adding extra hospital burdens.

In early tests using mouse models of breast cancer, supported by funding by Cancer Research UK and Medical Research Council (MRC), the drug made tumours more responsive to a range of commonly used chemotherapies. These promising results suggest it could be used across a wide variety of cancer types and chemotherapy treatments.

The researchers hope that with funding, clinical trials on breast and other cancers could begin within two years.

Professor James Spicer, Professor of Experimental Cancer Medicine, King’s College London, said: “Chemotherapy remains a key part of treatment for many patients with cancer, but too often it is not as effective or long-lasting as we might like. This research has identified a key reason for these limitations, and discovered a drug that we are keen to test in the clinic alongside established chemotherapy drugs”.

This breakthrough is the result of a multidisciplinary collaboration between researchers including Professors James Arnold, James Spicer, and Miraz Rahman and their research teams at King’s College London.

Professor Miraz Rahman, Professor of Medicinal Chemistry, King’s College London, said: “If human trials are successful, KCL-HO-1i could become a valuable companion drug to existing cancer therapies – helping more patients to benefit from the treatments that are already available and reduce the need for more aggressive cancer therapies in the future.”

Tanya Hollands, Research Information Manager at Cancer Research UK, added: “Researchers are increasingly learning how to make better use of existing cancer treatments, whether it’s using them differently or in combination with new medicines, like this work suggests. Using combination therapies can help bring improved treatment options to patients more quickly, safely and affordably, because some components of the treatment have already been tested and used in the clinic.

While early stage, it’s exciting to see this potential new way to disarm cancer’s ability to avoid detection by the immune system with a new drug, while also boosting the effectiveness of chemotherapy, and we look forward to seeing how this work progresses.”

Reference:

 Meriem Bahri et al, An oral heme oxygenase inhibitor targets immunosuppressive perivascular macrophages in preclinical models of cancer, Science Translational Medicine (2025). DOI: 10.1126/scitranslmed.ads3085

Powered by WPeMatico